Impaired Testicular Function in Patients With Carcinoma-In-Situ of the Testis

1999 ◽  
Vol 17 (1) ◽  
pp. 173-173 ◽  
Author(s):  
Peter Meidahl Petersen ◽  
Aleksander Giwercman ◽  
Steen W. Hansen ◽  
Jørgen G. Berthelsen ◽  
Gedske Daugaard ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Germ Cell ◽  
Leydig Cell ◽  
Carcinoma In Situ ◽  
Cell Function ◽  
Semen Quality ◽  
Sperm Concentration ◽  
Testicular Dysfunction ◽  
Leydig Cell Function

PURPOSE: To elucidate the biologic association between germ cell neoplasia and testicular dysfunction, through investigation of Leydig cell function and semen quality in men with carcinoma-in-situ (CIS) of the testis. PATIENTS AND METHODS: We examined two groups of men, unilaterally orchidectomized for testicular cancer. Biopsy of the contralateral testis had showed CIS in a group of 24 patients and no evidence of CIS in the other group of 30 patients. Semen quality and serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were compared in these two groups of men after orchidectomy but before further treatment for testicular cancer. RESULTS: Significantly higher LH levels (median, 8.1 IU/L v 4.8 IU/L; P < .001) and generally lower testosterone levels (median, 12.5 nmol/L v 15.5 nmol/L; P = .13) were found in the CIS group. The proportion of patients with Leydig cell dysfunction was higher in the group of patients with CIS (11 of 24) than in the group of patients without (two of 30) (P = .01). Sperm concentration and total sperm count were significantly lower (P < .001) in patients with CIS (median, 0.03 × 106/mL and 0.10 × 106, respectively) than in patients without (median, 9.1 × 106/mL and 32 × 106, respectively), whereas the levels of FSH were significantly higher (P < .001) in the former group of men (median, 19.6 IU/L v 9.0 IU/L). CONCLUSION: Not only spermatogenesis but also Leydig cell function is impaired in testes with CIS. This impairment could be due to common factors in the pathogenesis of germ cell neoplasm and testicular dysfunction. Alternatively, CIS cells may have a negative impact on Leydig cell function.

Effect of Graded Testicular Doses of Radiotherapy in Patients Treated for Carcinoma-In-Situ in the Testis

2002 ◽  
Vol 20 (6) ◽  
pp. 1537-1543 ◽  
Author(s):  
Peter Meidahl Petersen ◽  
Aleksander Giwercman ◽  
Gedske Daugaard ◽  
Mikael Rørth ◽  
Jørgen Holm Petersen ◽  
...  
Keyword(s):  
Dose Level ◽  
Leydig Cell ◽  
Carcinoma In Situ ◽  
Cell Function ◽  
Dose Range ◽  
Cell Cancer ◽  
Dose Dependency ◽  
Dose Levels ◽  
Leydig Cell Function

PURPOSE: To determine the effect of radiotherapy in doses 14 to 20 Gy on eradication of carcinoma-in-situ (CIS) testis and on the Leydig cell function. PATIENTS AND METHODS: Forty-eight patients presented with unilateral testicular germ cell cancer and CIS of the contralateral testis. The CIS-bearing testis was treated with daily irradiation doses of 2 Gy, 5 days a week, to a cumulative dose of 20 Gy (21 patients), 18 Gy (three patients), 16 Gy (10 patients), and 14 Gy (14 patients). RESULTS: All patients treated at dose levels 20 Gy to 16 Gy achieved histologically verified complete remission without signs of recurrence of CIS after an observation period of more than 5 years. One of 14 patients treated at dose level 14 Gy had a relapse of CIS 20 months after irradiation. Leydig cell function was examined before and regularly after radiotherapy in 44 of 48 patients. The levels of testosterone were lower after radiotherapy than before. Testosterone showed a stable decrease for more than 5 years after treatment (3.6% per year) without dose dependency. The levels of luteinizing hormone and follicle-stimulating hormone were increased after radiotherapy. The need of androgen substitution therapy was similar at all dose levels. CONCLUSION: Testicular irradiation is a safe treatment at dose level 20 Gy (10 × 2 Gy). Decrease of dose to 14 Gy (7 × 2 Gy) might lead to risk of relapse of CIS. Impairment of hormone production without clinically significant dose dependency is seen in the dose range 14 to 20 Gy.

scholarly journals Decrease in semen quality and Leydig cell function in infertile men: a longitudinal study

2018 ◽  
Vol 33 (11) ◽  
pp. 1963-1974 ◽  
Author(s):  
I A Olesen ◽  
U N Joensen ◽  
J H Petersen ◽  
K Almstrup ◽  
E Rajpert-De Meyts ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Leydig Cell ◽  
Cell Function ◽  
Semen Quality ◽  
Infertile Men ◽  
Leydig Cell Function

scholarly journals Compensated reduction in Leydig cell function is associated with lower semen quality variables: a study of 8182 European young men

2016 ◽  
Vol 31 (5) ◽  
pp. 947-957 ◽  
Author(s):  
N. Jørgensen ◽  
U.N. Joensen ◽  
J. Toppari ◽  
M. Punab ◽  
J. Erenpreiss ◽  
...  
Keyword(s):  
Leydig Cell ◽  
Cell Function ◽  
Semen Quality ◽  
Young Men ◽  
Leydig Cell Function

scholarly journals Effects of environmental Bisphenol A exposures on germ cell development and Leydig cell function in the human fetal testis

PLoS ONE ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. e0191934 ◽  
Author(s):  
Soria Eladak ◽  
Delphine Moison ◽  
Marie-Justine Guerquin ◽  
Gabriele Matilionyte ◽  
Karen Kilcoyne ◽  
...  
Keyword(s):  
Bisphenol A ◽  
Germ Cell ◽  
Leydig Cell ◽  
Cell Function ◽  
Cell Development ◽  
Germ Cell Development ◽  
Fetal Testis ◽  
Leydig Cell Function

2587 Pre-orchiectomy Leydig Cell function in testicular germ cell cancer (TGCC) patients

2015 ◽  
Vol 51 ◽  
pp. S507
Author(s):  
M. Bandak ◽  
N. Jørgensen ◽  
A. Juul ◽  
M.G.G. Kier ◽  
J. Lauritsen ◽  
...  
Keyword(s):  
Germ Cell ◽  
Leydig Cell ◽  
Cell Function ◽  
Cell Cancer ◽  
Germ Cell Cancer ◽  
Testicular Germ Cell ◽  
Testicular Germ Cell Cancer ◽  
Leydig Cell Function

Altered Leydig cell function in patients with testicular cancer: evidence for a bilateral testicular defect

1983 ◽  
Vol 102 (4) ◽  
pp. 616-624 ◽  
Author(s):  
P. H. B. Willemse ◽  
D. Th. Sleijfer ◽  
W. J. Sluiter ◽  
H. Schraffordt Koops ◽  
H. Doorenbos
Keyword(s):  
Testicular Cancer ◽  
Leydig Cell ◽  
Cell Function ◽  
Serum Levels ◽  
Group Iii ◽  
Testosterone Levels ◽  
Group I ◽  
Testicular Carcinoma ◽  
Group Ii ◽  
Leydig Cell Function

Abstract. In search of an abnormality in Leydig cell function in patients with testicular cancer, serum levels of testosterone, oestradiol, LH and FSH were compared in 3 groups of men. Group I comprised 26 patients studied after recent orchidectomy for a testicular carcinoma, group II 8 patients operated for benign testicular lesions and group III 8 normal controls. In group II normal testosterone values were found as a result of increased LH release. In group I patients, however, testosterone levels often were low, despite elevated LH levels and increased LH capacity. Evidently, in these patients a partial Leydig cell insufficiency may be present, which does not recover within one year of orchidectomy. After removal of one testis for benign disease, normal testosterone levels are maintained by increased LH levels. After orchidectomy for testicular carcinoma a partial Leydig cell insufficiency may be revealed, which seems to have a permanent character. A pre-existent Leydig cell insufficiency of the remaining testis in patients with testicular cancer indicates a bilateral testicular defect.

scholarly journals Benign Leydig cell tumour and germ cell carcinoma in situ in a young man with gynaecomastia.

1984 ◽  
Vol 60 (699) ◽  
pp. 66-69 ◽  
Author(s):  
R. S. Fink ◽  
M. S. Mann ◽  
J. P. Hopewell ◽  
J. Ginsburg
Keyword(s):  
Germ Cell ◽  
Cell Carcinoma ◽  
Leydig Cell ◽  
Carcinoma In Situ ◽  
Cell Tumour ◽  
Leydig Cell Tumour

Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance.

1990 ◽  
Vol 8 (10) ◽  
pp. 1695-1698 ◽  
Author(s):  
S W Hansen ◽  
J G Berthelsen ◽  
H von der Maase
Keyword(s):  
Testicular Cancer ◽  
Leydig Cell ◽  
Cell Function ◽  
Metastatic Cancer ◽  
Cell Cancer ◽  
Retroperitoneal Lymph Node Dissection ◽  
Cell Dysfunction ◽  
Previously Treated ◽  
Leydig Cell Function

Fertility and Leydig cell function were investigated in 31 patients previously treated for nonseminomatous testicular cancer. Twenty-two patients with metastatic cancer had received cisplatin-based chemotherapy, and the median follow-up was 64 months (range, 42 to 100 months). Nine patients without metastases were treated with orchiectomy alone, and follow-up in this group was a median of 61 months (range, 40 to 77 months). None of the patients have relapsed and retroperitoneal lymph node dissection was not performed in any patient. Both the concentration of spermatozoa and the volume of the remaining testis are significantly reduced in patients who had previously received chemotherapy when compared with patients treated with orchiectomy alone (P less than .05). There were no significant differences between groups when comparing morphology, motility, and penetration of the spermatozoa. Subclinical Leydig cell dysfunction with normal testosterone and elevated luteinizing hormone (LH) was observed in one patient (11%) treated with orchiectomy alone, while 59% of the patients who had received chemotherapy had elevated LH (P less than .05). We conclude that cisplatin-based chemotherapy leads to a persistent impairment of fertility and Leydig cell function in the majority of patients with testicular cancer.

Sign in / Sign up

Export Citation Format

Share Document